

Technology Appraisal Committee Meeting (Committee A)
10 Spring Gardens, London SW1A 2BU

Minutes: Confirmed

Date and Time: Tuesday 19 June 2018, 10:00 – 14:00

Present:	1. Dr Jane Adam (Chair)	Present for all notes
	2. Professor Iain Squire (Vice-Chair)	Present for all notes
	3. Dr Graham Ash	Present for all notes
	4. Dr Jeremy Braybrooke	Present for all notes
	5. Dr Justin Daniels	Present for all notes
	6. Dr Steve Edwards	Present for all notes
	7. Dr Rita Faria	Present for all notes
	8. Dr Rachel Hobson	Present for all notes
	9. Ms Pamela Rees	Present for all notes
	10. Dr Mohit Sharma	Present for all notes
	11. Mr Stephen Sharp	Present for all notes
	12. Dr Brian Shine	Present for all notes
	13. Dr John Watkins	Present for all notes
	14. Professor Olivia Wu	Present for all notes

In attendance:

Mirella Marlow	Interim Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Thomas Feist	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Sana Khan	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Eleanor Donegan	Technical Adviser, National Institute for Health and Care Excellence	Present for all notes
Irina Tikhonova	PenTAG, Evidence Review Group	Present for notes 1 to 3
Max Barnish	PenTAG, Evidence Review Group	Present for notes 1 to 3

Dr Tim Harrison	Clinical expert, Professor of Asthma and Respiratory Medicine	Present for notes 1 to 3
Dr Shuaib Nasser	Clinical expert, Consultant Physician in Allergy and Asthma	Present for notes 1 to 3
Lehanne Sergison	Patient expert	Present for notes 1 to 3
Olivia Allen	Patient expert	Present for notes 1 to 3

Non-public attendees:

Ana Uribe Echeverry	Corporate Office Coordinator, NICE	Present for all notes
Ria Skelton	Editor, NICE	Present for all notes
Hamish Lunagaria	Scientific Advice, NICE	Present for all notes
Heather Stegenga	Scientific Advice, NICE	Present for all notes
Sophia Lee	NICE Scholar	Present for all notes

Notes

Any other business

1. None.

Appraisal of benralizumab for treating severe eosinophilic asthma [ID1129]

Part 1 – Open session

2. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG) representatives and representatives from AstraZeneca.
3. The Chair asked all committee members, experts, ERG representatives and NICE staff present to declare any relevant interests.
 - 3.1. Dr Shuaib Nasser declared a personal specific financial interest as he has received payments for advisory boards for GSK, TEVA and Novartis. He declared a non-personal specific financial interest as he has undertaken clinical trials for GSK on mepolizumab, AstraZeneca for benralizumab, and Novartis.
 - 3.1.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.
 - 3.2. Dr Tim Harrison declared a personal specific financial interest as he has received payments for two advisory boards related to benralizumab. He has also received honorarium and expenses from AstraZeneca, Chiesi, GSK and Ventura. He declared a non-personal specific financial interest as his institution has received funds for research trials from AstraZeneca.
 - 3.2.1. It was agreed that this declaration would not prevent them from participating in this section of the meeting.
 - 3.3. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts, ERG representatives and members of the public were asked to leave the meeting)

4. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.
5. The committee decision was based on consensus.